This secondary analysis of the phase 1 CA209-003 clinical trial assesses the 5-year survival and other related factors among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer receiving nivolumab.
This cohort study examines the use of deep natural language processing in extraction of information on cancer outcomes from the medical records of patients with lung cancer.
This phase 2 randomized clinical trial assesses the safety and efficacy of durvalumab with and without tremelimumab for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
This biomarker analyss of patients with adrenocortical carcinoma compares the molecular classification for prognostic assessment of adrenocortical carcinoma with other known prognostic factors.
This phase 2 multicenter randomized clinical trial including 88 patients compares progression-free survival, and secondarily overall survival, overall response rate, and adverse events, in patients with stage 4 EGFR-mutant non–small cell lung cancer treated with erlotinib plus bevacizumab vs erlotinib alone.
This cohort study examines the neurocognitive and neuroimaging outcomes associated with multiple use of general anesthesia in survivors of childhood acute lymphoblastic leukemia.
This phase 1/2 trial evaluates the toxic effects, maximally tolerated dose, and recommended phase 2 dose of the protease inhibitor nelfinavir administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer, and estimates the objective response rate, local and distant failure rates, and overall and progression-free survival.
This database study assesses the frequency of race reporting and proportional race representation in trials that support FDA oncology drug approvals.
This survey study analyzes NHIS data from nearly 18 000 patients with a cancer diagnosis before and after implementation of the Affordable Care Act (ACA) to evaluate patterns and patient-reported reasons for not having health insurance before and after the ACA.
This validation study assesses the clinical validity of molecular relapse detection with circulating tumor DNA analysis in early-stage breast cancer.
This exploratory pooled analysis of 11 randomized clinical trials examines whether the lung immune prognostic index is associated with long-term outcomes of treatment with immune checkpoint inhibitors and targeted therapy for patients with metastatic non–small cell lung cancer.
This database study assesses the number of female lead investigators of randomized clinical trials registered in ClinicalTrials.gov.
This survey study evaluates the association of gender and parenthood status with conference attendance among career oncologists.
This cohort study analyzes the medical records of 47 721 patients with various cancer types with POLE/POLD1 mutations to evaluate whether the mutations were associated with immunotherapy outcomes.
This genetic association study examines the prevalence of pathogenic/likely pathogenic germline variants among patients with metastatic breast cancer.
This review examines the differences in the epidemiology, tumor and host biology, and treatment of breast cancer in the East compared with the West.
A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What is your diagnosis?
This Viewpoint examines the components and benefits of a systems approach to meeting the challenges of global oncology.
This Viewpoint asuggests that a clear quantitative presentation of the assumptions and expectations used in the planning of clinical trials should be included in written consent forms.
This Viewpoint discusses the need for academic medical leaders to emphasize education and research on supportive and palliative care programs to address physical and psychosocial pain in patients with cancer.
This article describes the experiences of a first-year oncology fellow’s experience as he treats his first patient.
Create a personal account or sign in to: